Cormack Scott Daniel 4

4 · ACHIEVE LIFE SCIENCES, INC. · Filed Aug 3, 2017

Form 4

Period: 2017-08-01

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
2017-08-01+3,125→ 16,302 total
Exercise/Conversion
Common Stock
2017-08-01+1,590→ 9,685 total(indirect: By Spouse)
Exercise/Conversion
Restricted Stock Unit (RSU)
2017-08-01−568→ 0 total
Exp: 2018-04-13→ Common Stock (568 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2017-08-01−1,705→ 0 total
Exp: 2019-06-18→ Common Stock (1,705 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2017-08-01−284→ 0 total(indirect: By Spouse)
Exp: 2018-04-13→ Common Stock (284 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2017-08-01−852→ 0 total(indirect: By Spouse)
Exp: 2019-06-18→ Common Stock (852 underlying)
Award
Stock Option (right to buy)
2017-08-01+11,000→ 11,000 total
Exercise: $4.57From: 2018-08-01Exp: 2027-08-01→ Common Stock (11,000 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2017-08-01−852→ 0 total
Exp: 2018-06-12→ Common Stock (852 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2017-08-01−454→ 0 total(indirect: By Spouse)
Exp: 2018-06-12→ Common Stock (454 underlying)

Holdings

Stock Option (right to buy)
Exercise: $129.69Exp: 2024-03-14→ Common Stock (4,545 underlying)
4,545
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $156.20Exp: 2020-06-08→ Common Stock (318 underlying)
318
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $185.13Exp: 2021-01-03→ Common Stock (3,181 underlying)
3,181
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $131.45Exp: 2023-03-12→ Common Stock (1,818 underlying)
1,818
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $20.46Exp: 2015-05-19→ Common Stock (3,409 underlying)
3,409
Stock Option (right to buy)
Exercise: $175.67Exp: 2020-12-14→ Common Stock (3,636 underlying)
3,636
Stock Option (right to buy)
Exercise: $143.00Exp: 2022-05-08→ Common Stock (3,409 underlying)
3,409
Stock Option (right to buy)
Exercise: $245.08Exp: 2019-12-31→ Common Stock (2,272 underlying)
2,272
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $143.00Exp: 2022-05-08→ Common Stock (1,363 underlying)
1,363
Stock Option (right to buy)
Exercise: $131.45Exp: 2023-03-12→ Common Stock (3,409 underlying)
3,409
Stock Option (right to buy)
Exercise: $20.46Exp: 2025-05-19→ Common Stock (6,818 underlying)
6,818
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $129.69Exp: 2024-03-14→ Common Stock (2,272 underlying)
2,272

Footnotes (5)

[F1]Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. On August 1, 2017, the effective date of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. (the "Merger"), the closing price of Achieve Life Sciences, Inc.'s common stock was $4.576 per share, representing a closing price of $0.416 per share of Oncogenex common stock as adjusted to reflect an 11-to-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
[F2]Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.
[F3]Pursuant to the terms of the reporting holder's employment agreement, the RSUs immediately vested in full on August 1, 2017, in connection with the consummation of the Merger.
[F4]Reflects the Reverse Stock Split.
[F5]Pursuant to the terms of the reporting holder's spouse's consulting agreement, the RSU immediately vested on August 1, 2017, in connection with the consummation of the Merger.

Documents

1 file